Copper Metabolism Genes and SNPs

Copper biology is partly genetic.

That matters most when copper status and treatment response may be linked through the same transport pathways.

Why these genes matter

Some of the same transporters that move copper also move platinum drugs.

That means variants or altered expression in these genes can affect both copper handling and drug response.

The strongest practical use here is not self-interpretation.

It is knowing which genes are worth flagging if you already have germline data, tumour genomics, or raw data from a consumer test.

Key genes to know

SLC31A1 (CTR1)

This is the main copper importer.

It also helps import cisplatin and carboplatin.

Variants and altered expression may affect copper homeostasis, cuproptosis sensitivity, and platinum-drug entry into cells.

ATP7B

This is a copper exporter.

It also helps efflux cisplatin.

Higher activity or clinically relevant variants may contribute to platinum resistance in some cancers.

ATP7A

This is another copper exporter.

It has been linked to angiogenic signalling and may also affect treatment response patterns in selected tumour types.

SLC25A3 and SLC25A37

These transporters influence mitochondrial metal handling.

That makes them relevant to cuproptosis biology inside mitochondria.

ATOX1

ATOX1 is a copper chaperone.

It has been linked with tumour angiogenesis and copper delivery into signalling systems that support tumour growth.

Who should pay closest attention

This is most relevant if you are:

• about to start cisplatin, carboplatin, or oxaliplatin

• already showing unusual copper accumulation during treatment

• on an anti-angiogenic regimen

• reviewing genomic data for treatment-resistance clues

Practical use

If you already have genomic data, flag these genes for a practitioner who understands transporters and oncology pharmacology.

Do not over-interpret single SNPs in isolation.

Gene expression, tumour context, and the treatment plan matter more than raw genotype alone.

Practical takeaway

For most people, the first step is still serum copper plus ceruloplasmin.

Gene review becomes more useful when there is a clear treatment question, especially around platinum drugs or unusual copper patterns.

Key References

Pan-cancer genetic analysis of cuproptosis and copper metabolism https://pmc.ncbi.nlm.nih.gov/articles/PMC9582932/

Pan-cancer analysis: copper transporters as biomarkers https://pmc.ncbi.nlm.nih.gov/articles/PMC11402228/

Cuproptosis-related genes SLC31A1, FDX1, ATP7B in lung cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC9342429/

Copper metabolism in hepatocellular carcinoma https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1578693/full